Figure 7.

DUXAP9 promoted renal cancer cells invasion, migration and proliferation via Akt pathway activation. (A) Western blots were performed to evaluate the key Akt pathway proteins levels after overexpression of DUXAP9 treated with or without LY294002. (B, C) 786O cells with DUXAP9 overexpression were treated with or without LY294002 and measured through the Transwell chamber without/with Matrigel. (D, E) 786O cells with DUXAP9 overexpression were treated with or without LY294002 and subjected to wound‐healing assays. (F) 786O cells with DUXAP9 overexpression were treated with or without LY294002 and subjected to CCK-8 assays. (G, H) 786O cells with DUXAP9 overexpression were treated with or without LY294002 and subjected to colony formation assays. Data represent mean ± SD from three independent experiments. OE, DUXAP9 overexpression; NC, overexpression negative control; CCK-8, cell counting kit-8; *P < 0.05; **P < 0.01; ***P < 0.001.